Ask AI
ProCE Banner Activity

CE

Bridging IgAN Care: Nurse-Led Strategies for Management and Treatment With Novel ​Disease-Modifying Therapies

Video

In this interactive webcast, learn from IgAN experts as they consider current treatment approaches, new and emerging therapies, and case-based examples of nurse-led strategies to optimize care. Also benefit from featured clinical perspectives and new evidence incorporated since the live symposium.

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: July 16, 2025

Expiration: July 15, 2026

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners) 

ProCE Banner

Supporters

Supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Otsuka America Pharmaceutical, Inc.

Target Audience

This activity is intended for nephrology nurses and nurse practitioners who care for patients with IgAN. 

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with IgAN.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Differentiate the roles of complement, endothelin, and APRIL/BAFF pathways in the pathogenesis of IgAN

  • Integrate knowledge of the mechanistic differences and clinical efficacy and safety data on new and emerging IgAN therapies to individualize patient treatment plans

  • Develop nurse-led strategies for management and treatment focused on reducing proteinuria to slow disease progression and enhance patient outcomes in IgAN

Disclosure

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partner policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Wooin Ahn, MD, PhD, has no relevant financial relationships to disclose.

Kelly B. Chen, BSN, MSN, AGACNP-BC: consultant/advisor/speaker: Alpine, Novartis, Otsuka, Travere.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 16, 2025, through July 15, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (Partners) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacotherapy credit.